Projenx

Developer of targeted therapies to treat amyotrophic lateral sclerosis (ALS)

placeNew York City, New York, United States calendar_todayFounded 2021 groups4 employees language projenx.com

Social engagement

Social engagement: 721 social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

2 investors on record; lead investors include Medical Excellence Capital.

Investor typeCountShare
Venture capital150%
Other / undisclosed150%

Recent activity

22 Apr 2026
Milestone
users
9 Oct 2025
Event
The Leadership Imperative: Guiding Therapies and Biomedicine from Vision to Impact
Coming soon